MarginsXMarginsX
Home › Markets › Health Care › VIVS

VivoSim Labs Inc. (VIVS)

VIVS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.1237
-2.68% on the day
Market cap
$2.5M
Nano cap
Revenue · 2025
$131K
-9.0% on 2024
Net income · 2025
-$13.8M
-10567.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1497253/000119312526303316/0001193125-26-303316-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-03-31.

Profile

FieldValue
TickerVIVS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001497253
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$131K
Net income-$13.8M
Operating income-$11.5M
Net margin-10567.2%
Operating margin-8768.7%
Revenue growth-9.0%
Cash$5.0M
Total assets$7.4M
P/E (computed)Net income was not positive
P/S (computed)19.2×

Warning signs

Cash runway
10.1 months
$8.6M cash at September 30, 2026
Share count, 1 year
+677.7%
2025-11-01 to 2026-11-01 · +2654.0% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
-$5K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The Company has concluded that the prevailing conditions and ongoing liquidity risks faced by the Company raise substantial doubt about its ability to continue as a going concern for at least one year following the date these condensed consolidated financial statements are issued."
10-Q 2026-11-12
Cash and burn$8.6M cash; operating cash flow -$2.5M a quarter.Report 2026-09-30
Shares outstanding20,281,495 (2026-11-01); 2,607,962 a year earlier; 8,837,095 three years earlier. 3y figure adjusted for splits (1-for-12 overall).Cover page 2026-11-01
Reverse splits, 3 years1; latest 1-for-12 on 2025-03-21Source 2025-03-21
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-08-21
AuditorRosenberg Rich Baker Berman, P.A., Somerset, New Jersey, United StatesPCAOB Form AP 2026-07-23
Late filings, 12 months1 NT noticeNT 10-K 2026-06-29
Insider trades, 12 monthsBought $3K, sold $7K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2027
2026-09-30
$51K-$475K-$2.5M$8.6MNo debt tags$135K10-Q 2026-11-12
Q1 2027
2026-06-30
$18K-$1.3M-$3.2M$1.7MNo debt tags$112K10-Q 2026-08-12
Q4 2026
2026-03-31
$40K-$5.8M-$2.2M$5.0MNo debt tags$131K10-K 2026-07-14
Q3 2026
2025-12-31
$26K-$2.7M-$2.3M$4.3MNo debt tags$142K10-Q 2026-02-11
Q2 2026
2025-09-30
$28K-$2.5M-$2.4M$6.7MNo debt tags$140K10-Q 2026-11-12
Q1 2026
2025-06-30
$37K-$2.8M-$3.9M$9.1MNo debt tags$142K10-Q 2026-08-12
Q4 2025
2025-03-31
$51K$6.9M-$2.0M$11.3MNo debt tags$144K10-K 2026-07-14
Q3 2025
2024-12-31
$24K-$3.4M-$1.8M$1.2MNo debt tags$122K10-Q 2026-02-11

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-12026-07-31
Latest annual report10-K2026-07-14
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-10-16
Latest proxyDEF 14A2026-08-21

Source: SEC EDGAR submissions feed, 820 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-7.1%
1 month-23.5%
3 months-60.6%
Year to date-92.8%
1 year-93.9%
From 52-week high-95.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CLDICalidi Biotherapeutics Inc.$0.6023-3.15%$2.2M
CELZCreative Medical Technology Holdings Inc.$0.5201-1.51%$4.0M
LIMNLiminatus Pharma Inc.$2.97-0.67%$4.0M
CRISCuris Inc.$0.4358-2.07%$4.1M
BTTCBlack Titan Corporation$0.2873-9.20%$4.3M
AIMAIM ImmunoTech Inc.$0.1310-8.77%$5.2M
SNTISenti Biosciences Holdings Inc.$0.1360-2.86%$5.2M
SLXNSilexion Therapeutics Corp$1.76-11.11%$1.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier